PRESS RELEASE
Shanghai, China – July 1, 2026
Gluetacs Therapeutics Receives CDE Clinical Trial Approval for First-in-Class Bifunctional RSK Degrader GT818
Gluetacs Therapeutics' GT818, a first-in-class bifunctional RSK degrader, has received clinical trial implied approval from China's Center for Drug Evaluation (CDE). GT818 was developed utilizing Gluetacs proprietary GlueTacs® platform. The upcoming phase I clinical study will evaluate the safety, tolerability and preliminary anti-tumor efficacy of GT818 monotherapy in patients with advanced malignancies including solid tumors.
About Gluetacs Therapeutics
Gluetacs Therapeutics, focusing on the development of oral small molecule protein degrader, is the first biotech company incubated from ShanghaiTech University, Gluetacs was founded in February 2020, and started to operation in March 2021. It was found by several scientists that have done intensive studies in target protein degradation. The company has independent intellectual property of GLUE degrader and GLUETAC degrader development platform with around 100 patents filed, which has indicated a unique and differentiated technical route and development strategy. The company has established artificial intelligence virtual screening platform, in vitro pharmacodynamics screening platform, pharmacokinetics platform, proteomics platform and in vivo drug pharmacology evaluation platform, and has constructed a complete whole-process drug R&D system. Since launching operations in March 2021, Gluetacs Therapeutics has successfully advanced 3 drug candidates into clinical trial. Gluetacs’ therapeutic focus spans multiple areas including hematologic malignancies, solid tumors, autoimmune diseases, and rare diseases, consistently upholding a patient-centric development philosophy.
